Baricitinib in the Treatment of Severe Atopic Dermatitis Resistant to Cyclosporine: A Case Report Involving Two Cases
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that profoundly affects quality of life, particularly in patients with moderate-to-severe disease that is refractory to conventional treatments. Cyclosporine is a cornerstone of systemic therapy for severe AD; however, its long-term use is hindered by toxicity, and effective alternatives are often unavailable or insufficient. Janus kinase inhibitors, including baricitinib, have emerged as promising therapeutic options by modulating key inflammatory pathways involved in AD pathogenesis. This report describes two cases of severe cyclosporine-refractory AD that were successfully managed with baricitinib. Both patients showed substantial clinical improvement, including significant reductions in affected body surface area, disease severity scores, pruritus, and sleep disturbances within four weeks of initiating treatment. No serious adverse effects were observed, and the treatment was well tolerated. These findings highlight the potential of baricitinib as a viable therapeutic alternative for severe AD, particularly in settings where biologics such as dupilumab or abrocitinib may be limited. While baricitinib demonstrates both rapid and sustained efficacy, further studies are warranted to confirm its long-term safety and define its optimal role in AD management.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Artificial Intelligence in Medicine: Cross-Sectional Study Among Medical Students on Application, Education, and Ethical Aspects
- Information quality of videos related to esophageal cancer on tiktok, kwai, and bilibili: a cross-sectional study
- The quality and reliability of short videos about hypertension on TikTok: a cross-sectional study
- Quality and reliability evaluation of pancreatic cancer-related video content on social short video platforms: a cross-sectional study
- Quality and reliability of pediatric pneumonia related short videos on mainstream platforms: cross-sectional study
- Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007–2018
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.